---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-143658"
form_type: "8-K"
ticker: "IOBTQ"
cik: "0001865494"
company_name: "IO Biotech, Inc."
filed_at: "2025-06-20T23:59:59+00:00"
generated_at: "2026-05-19T01:52:49.970430+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# IO Biotech enters CEO severance agreement providing 12-18 months pay and equity vesting

## Summary
- Severance pay: 12 months base salary on qualifying termination; 18 months if termination within 6 months pre- or 12 months post-Change in Control.
- Equity awards: 12-month vesting acceleration (standard) or 100% vesting at target (Change in Control scenario).
- Pro-rated bonus for termination year plus unpaid prior-year bonus; subject to release and non-compete compliance.
- CEO Mai-Britt Zocca: addendum to existing service agreement effective June 19, 2025.

## SEC filing metadata
- accession: 0001193125-25-143658
- form_type: 8-K
- ticker: IOBTQ
- cik: 0001865494
- company_name: IO Biotech, Inc.
- filed_at: 2025-06-20T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1865494/000119312525143658/0001193125-25-143658-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1865494/000119312525143658/d90779d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-143658
- JSON: https://secwatch.observer/filing/0001193125-25-143658.json
- Plain text: https://secwatch.observer/filing/0001193125-25-143658.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.